查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1738728

全球癌症疫苗市場規模：按疫苗類型、按癌症類型、按技術、按最終用戶、按地區和預測

Global Cancer Vaccine Market Size By Type of Vaccine, By Type of Cancer, By Technology, By End User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

癌症疫苗市場規模及預測

預計 2024 年癌症疫苗市場規模將達到 100.4 億美元，到 2032 年將達到 174.9 億美元，2026 年至 2032 年的複合年成長率為 7.93%。

癌症疫苗是一種免疫療法，旨在增強免疫系統識別和對抗癌細胞的能力。這些疫苗針對癌細胞上的特定抗原，引發免疫反應，清除惡性腫瘤細胞，同時保留健康組織，從而防止癌症形成或復發。癌症疫苗既可以預防特定惡性腫瘤，也可以治療現有癌症，透過增強免疫監測和對癌細胞的反應來治療。該領域的研究重點是根據患者的個別特徵開發個人化疫苗，並利用新型免疫技術來提高疫苗療效。

癌症疫苗既可用於預防癌症，也可用於治療癌症。預防性癌症疫苗，例如針對子宮頸癌的人類乳突病毒 (HPV) 疫苗，旨在透過靶向已知致癌的感染性微生物來預防癌症的發生。另一方面，治療性癌症疫苗旨在透過激活免疫系統識別並摧毀癌細胞來治療活躍的癌症。這些疫苗可以單獨使用，也可以與其他治療方法（例如手術、化療或標靶治療）合併使用，以增強人體對腫瘤的免疫反應。目前正在進行的研究正在探索新的疫苗接種目標、給藥策略和聯合治療，以改善癌症患者的預後。

癌症疫苗有可能成為根據個人基因圖譜和腫瘤特徵量身定做的個人化醫療技術的關鍵組成部分。免疫療法和生物標記研究的進展有望帶來更有效的疫苗，這些疫苗可以靶向更廣泛的惡性腫瘤並誘導持久的免疫反應。奈米顆粒和病毒載體是兩種疫苗遞送系統的創新，它們可以提高療效並減少副作用。此外，人工智慧和基因組分析的應用可以透過預測患者預後並提案合適的治療方法組合來改善疫苗研發。隨著研究的進展，癌症疫苗有望在癌症治療模式轉向更有針對性、毒性更低且具有潛在治癒力的藥物轉變中發揮關鍵作用。

癌症疫苗市場動態

影響癌症疫苗市場的關鍵市場動態是：

關鍵市場促進因素

癌症發生率不斷上升：隨著全球癌症發生率的上升，對有效預防和治療方案的需求也日益成長，例如針對特定癌症類型的疫苗。疫苗具有降低癌症風險和復發的潛力，對醫療保健專業人士和尋求預防性治療方法的人具有吸引力。

免疫療法的進展：免疫療法在癌症治療中產生的革命性影響，促使人們研究癌症疫苗作為一種強大的免疫療法。疫苗透過激活免疫系統識別並殺死癌細胞，有助於制定個人化治療方法，並為對常規藥物無效的患者帶來新的希望。

政府計劃與資金籌措：政府資助的計劃與資金正在幫助加速癌症疫苗的研發。監管激勵措施、津貼以及官民合作關係為臨床試驗、監管核准和市場准入提供支援。這些計畫促進疫苗創新和相關人員合作，以解決癌症治療領域尚未滿足的醫療需求。

主要問題

複雜的癌症生物學：癌症生物學非常複雜，包含多種亞型和基因異常，因此很難找到通用的疫苗標靶。腫瘤異質性和免疫逃脫機制使疫苗的配製和療效面臨挑戰，因此精準的抗原選擇和個人化治療對於改善治療效果至關重要。

臨床試驗設計與檢驗：確定癌症疫苗的目標、病患選擇和臨床試驗設計都極具挑戰性。確定疫苗效力通常需要長期追蹤、複雜的生物標記分析以及嚴格的監管審查。此外，由於免疫反應因患者而異，因此需要進行大規模、多樣化的測試隊列來驗證疫苗效力。

市場准入與商業化：癌症疫苗進入市場需要與監管機構談判、獲得報銷核准並克服定價挑戰。高昂的開發成本、來自現有企業的競爭以及醫療專業人員和患者對疫苗接受度的不確定性阻礙了商業性成功。策略聯盟和遊說活動是克服這些障礙並確保疫苗廣泛可及的關鍵。

主要趨勢

個人化醫療方法：根據患者個別情況客製化癌症疫苗的趨勢日益成長。基因序列測定和生物標記辨識技術的進步使得針對患者腫瘤中發現的特定突變和新抗原的疫苗研發成為可能。這種個人化方法透過最大限度地提高針對腫瘤特異性抗原的免疫反應來提高疫苗效力。

聯合療法：人們越來越關注將癌症疫苗與其他免疫療法（例如查核點抑制劑和細胞激素療法）合併使用，以改善治療效果。疫苗和免疫調節藥物的協同效應旨在增強免疫激活，克服腫瘤微環境中的免疫抑制，並改善患者對治療的反應。

疫苗遞送技術的創新：提升疫苗效力和效能。奈米顆粒、病毒載體和基於樹突狀細胞的疫苗接種技術能夠實現標靶抗原遞送、擴大呈現抗原並增強免疫活化。這些改進旨在提高疫苗效力，同時最大限度地減少副作用，從而加速下一代癌症疫苗的研發。

癌症疫苗市場區域分析

以下是癌症疫苗市場更詳細的區域分析：

北美洲

據Verified Market Research分析師稱，北美佔據了癌症疫苗市場的最大市場佔有率。該地區擁有強大的研發能力，並擁有雄厚的資金和基礎設施。北美的大型製藥企業和研究機構正在推動癌症疫苗技術的創新，加速臨床試驗，並將新藥推向市場。

北美的監管體係有利於加速疫苗研發和批准。美國藥物管理局（FDA）等機構簡化了包括疫苗在內的生技藥品製劑的監管途徑，使其比其他地區更快進入市場。這種高效的監管模式鼓勵了投資，並創造了競爭環境，使企業能夠快速將新型癌症疫苗帶給患者。

北美穩健的醫療環境和高昂的醫療支出正在推動癌症疫苗等新型療法的普及。該地區完善的醫療基礎設施為患者提供了獲得尖端治療方法的機會，為新型免疫接種的商業化和推廣創造了良好的環境。學術界、產業界和醫療機構之間的合作關係也促進了知識交流和創新免疫療法的應用，鞏固了北美在全球癌症疫苗市場的領導地位。

亞太地區

亞太地區的癌症疫苗市場蓬勃發展。該地區人口快速成長，癌症發生率不斷上升，推動了對新型治療方法的需求，其中包括癌症疫苗。由於人口老化、生活方式改變和環境因素，中國、印度和日本等國家的癌症發生率不斷上升，這推動了癌症疫苗市場的發展。

亞太地區正受惠於醫療基礎設施和研究能力投資的不斷增加。該地區的政府和私人企業正在大力投資醫療保健系統和生物製藥研發。這些投資推動了癌症疫苗技術、臨床試驗和監管核准的改進，促進了市場的快速擴張。

亞太地區癌症疫苗的普及得益於醫療法規的不斷變化，以及醫護人員和患者對免疫療法和個人化醫療益處的日益了解。該地區人口結構和基因特徵的多樣性要求採用個人化的治療方法，這與強調根據患者俱體特徵標靶治療的個人化醫療趨勢相一致。

癌症疫苗市場區隔分析

癌症疫苗市場根據疫苗類型、癌症類型、技術、最終用戶和地區進行細分。

癌症疫苗市場（以疫苗類型）

  • 預防性疫苗
  • 治療性疫苗

根據疫苗類型，市場分為預防性疫苗和治療性疫苗。治療性癌症疫苗目前佔據市場主導地位，因為它們旨在治療現有癌症病例。這些疫苗能夠激活免疫系統識別並靶向癌細胞，從而阻止疾病發展並改善患者預後。雖然像人類乳突病毒(HPV)疫苗這樣的預防性疫苗在降低癌症發生率方面發揮著重要作用，但治療性疫苗則瞄準當前的醫療需求，並展現出透過個人化免疫治療技術改善癌症治療方案的巨大潛力。

癌症疫苗市場（按癌症類型分類）

  • 子宮頸癌
  • 攝護腺癌
  • 肺癌
  • 乳癌

根據癌症類型，市場分為子宮頸癌、前列腺癌、肺癌和乳癌，其中乳癌乳癌，因為其在世界範圍內發病率高，並且正在積極研究針對特定乳癌抗原的疫苗接種等治療方法，以改善治療效果和存活率。

癌症疫苗市場（按技術）

  • 胜肽類疫苗
  • 樹突細胞疫苗
  • 基於載體的疫苗
  • DNA/RNA疫苗

根據技術，市場細分為胜肽類疫苗、樹突細胞疫苗、載體疫苗和DNA/RNA疫苗。肽類疫苗目前在癌症疫苗市場佔據主導地位，因為它們能夠精準靶向腫瘤抗原，從而增強針對癌細胞的免疫反應，並最大限度地減少脫靶效應，使其成為個人化免疫治療的理想選擇。

癌症疫苗市場（按最終用戶分類）

  • 醫院和診所
  • 癌症研究所
  • 生物製藥公司
  • 政府和非營利組織

根據最終用戶，市場分為醫院診所、癌症研究機構、生物製藥公司、政府機構和非營利組織。醫院診所佔據主導地位，因為它們提供全面的醫療保健服務和癌症相關需求的管理，直接為患者提供疫苗接種、癌症治療和診斷服務。

癌症疫苗市場（按地區）

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 拉丁美洲

根據區域分析，市場分為四個區域：北美、歐洲、亞太地區、拉丁美洲和中東及非洲。北美在全球癌症疫苗產業佔據主導地位有幾個關鍵原因。該地區受益於現代化的醫療基礎設施、大量的研發支出以及強力的法規環境，有助於快速核准和推出新型治療方法。北美大型製藥企業正在利用其廣泛的臨床實驗室網路和與頂尖研究機構的合作關係，率先開發新型癌症疫苗。此外，高昂的醫療支出和龐大的患者群體正在推動癌症疫苗的廣泛採用，鞏固了北美在這一重要醫療領域的領導地位。

主要參與企業

  • 全球癌症疫苗市場研究報告提供了針對全球市場的寶貴見解。市場主要企業包括葛蘭素史克、默克公司、輝瑞、賽諾菲巴斯德、CSL有限公司、Astellas來製藥和印度血清實驗室。

我們的市場分析還包括針對這些關鍵公司的專門部分，我們的專家將在其中提供有關其財務報表、產品基準和 SWOT 分析的見解，而競爭格局部分還包括上述全球競爭對手的關鍵發展策略、市場佔有率和市場排名分析。

  • 癌症疫苗市場的最新趨勢：
  • 2023年9月，奈及利亞聯邦政府即將推出人類乳突病毒（HPV）疫苗，以挽救該國數百人的生命，並減少該國少女的子宮頸癌病例數。
  • 繼2022年1月推出針對新冠病毒的mRNA疫苗後，生技公司Moderna和BIoTech宣布正在研發癌症疫苗。英國癌症研究中心（CRUK）高級研究資訊經理Sam Godfrey談到了mRNA癌症疫苗的研發進展。
  • 2023 年 8 月，衛生部長史蒂芬唐納利 (Stephen Donnelly) 宣布擴大勞拉布倫南 HPV（人類乳突病毒）疫苗補種計劃，將所有 22 歲以下的男孩納入其中。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查方法

第2章執行摘要

  • 主要發現
  • 市場概覽
  • 市場亮點

第3章市場概述

  • 市場規模和成長潛力
  • 市場趨勢
  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析

第4章 癌症疫苗市場（依疫苗類型）

  • 預防性疫苗
  • 治療性疫苗

第5章 癌症疫苗市場（依癌症類型）

  • 子宮頸癌
  • 攝護腺癌
  • 肺癌
  • 乳癌
  • 其他癌症

第6章 癌症疫苗市場（依技術）

  • 胜肽類疫苗
  • 樹突細胞疫苗
  • 基於載體的疫苗
  • DNA/RNA疫苗

第7章 癌症疫苗市場（依最終用戶）

  • 醫院和診所
  • 癌症研究所
  • 生物製藥公司
  • 政府和非營利組織

第8章區域分析

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 智利
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章市場動態

  • 市場促進因素
  • 市場限制
  • 市場機會
  • COVID-19 市場影響

第10章 競爭格局

  • 主要企業
  • 市場佔有率分析

第11章 公司簡介

  • ABB（瑞士）
  • 西門子股份公司（德國）
  • 瓦錫蘭（芬蘭）
  • 康斯伯格集團（挪威）
  • Leclanche SA（瑞士）
  • 通用動力電船公司（美國）
  • Corvus Energy（挪威）

第12章 市場展望市場展望與機會

  • 新興技術
  • 未來市場趨勢
  • 投資機會

第13章 附錄

  • 簡稱列表
  • 來源和參考文獻
簡介目錄
Product Code: 37308

Cancer Vaccine Market Size and Forecast

Cancer vaccine market size was valued at USD 10.04 Billion in 2024 and is projected to reach USD 17.49 Billion by 2032, growing at a CAGR of 7.93% from 2026 to 2032.

Cancer vaccines are immunotherapy treatments that boost the immune system to recognise and fight cancer cells. These vaccines attempt to prevent cancer formation or recurrence by targeting specific antigens found on cancer cells eliciting an immune response that eliminates malignant cells while preserving healthy tissue. Cancer vaccines can be preventive meaning they are designed to prevent specific malignancies or therapeutic meaning they are used to treat existing cancer by improving immune surveillance and reaction against tumour cells. This field's research focuses on creating personalized vaccinations based on individual patient characteristics and enhancing efficacy using novel immunological techniques.

Cancer vaccines are used for both prevention and treatment in oncology. Prophylactic cancer vaccines such as human papillomavirus (HPV) vaccinations for cervical cancer seek to prevent disease development by targeting infectious organisms known to cause cancer. Therapeutic cancer vaccines on the other hand are intended to treat active cancers by activating the immune system to recognise and destroy cancer cells. These vaccinations can be administered alone or in conjunction with other treatments like as surgery, chemotherapy, or targeted therapy to boost the body's immune response to tumors. Ongoing research investigates new vaccination targets, delivery strategies, and combination medicines to improve cancer patient outcomes.

Cancer vaccines have the potential to become key components of personalized medicine techniques that are tailored to individual genetic profiles and tumour features. Advances in immunotherapy and biomarker research are likely to result in more effective vaccinations that can target a broader range of malignancies and trigger long-lasting immune responses. Nanoparticles and viral vectors are two vaccine delivery system innovations that may improve efficacy while reducing side effects. Furthermore, using artificial intelligence and genomic analysis could improve vaccine development by predicting patient outcomes and suggesting appropriate therapy combinations. Cancer vaccines as research advances are poised to play a critical role in shifting cancer therapy paradigms towards more focused, less toxic, and potentially curative medicines.

Cancer Vaccine Market Dynamics

The key market dynamics that are shaping the cancer vaccine market include:

Key Market Drivers:

Growing Cancer Incidence: As worldwide cancer rates rise, so does the demand for effective preventative and treatment options such as vaccines that target specific cancer types. Vaccines have the potential to reduce cancer risk and recurrence which appeals to healthcare practitioners and people looking for proactive therapies.

Advancements in Immunotherapy: The revolutionary impact of immunotherapy on cancer treatment has prompted research into cancer vaccines as a powerful immunotherapeutic approach. Vaccines contribute to personalised treatment regimens by activating the immune system to recognise and kill cancer cells giving patients who have not responded to traditional medicines new hope.

Government Efforts and Financing: Government-supported efforts and financing help to accelerate cancer vaccine research and development. Regulatory incentives, grants, and public-private partnerships help with clinical trials, regulatory approvals, and market access. These programmes promote vaccine innovation and stakeholder collaboration to address unmet medical requirements in cancer care.

Key Challenges:

Cancer Biology Complex: Cancer biology is complex, with many subtypes and genetic abnormalities making it difficult to identify universal vaccine targets. Tumour heterogeneity and immune evasion mechanisms challenge vaccine formulation and efficacy necessitating precise antigen selection and personalised approaches to improve therapeutic outcomes.

Clinical Trial Design and Validation: Determining objectives, selecting patients, and designing trials for cancer vaccines are all challenging. Long-term follow-up periods, complicated biomarker analysis, and rigorous regulatory scrutiny are frequently required to determine vaccine efficacy. Furthermore, because immune responses vary between patients, large and diverse study cohorts are required to establish vaccine efficacy.

Market Access and Commercialization: Gaining market access for cancer vaccines entails negotiating regulatory procedures obtaining reimbursement approvals, and overcoming pricing difficulties. Commercial success is hampered by high development costs, competition from current medicines, and uncertainty about vaccine acceptance among healthcare professionals and patients. Strategic alliances and lobbying initiatives are critical for overcoming these barriers and ensuring widespread vaccine access.

Key Trends:

Personalised Medicine Approach: There is a growing trend of cancer vaccinations that are tailored to individual patient profiles. Advances in genomic sequencing and biomarker identification enable the development of vaccinations that target specific mutations or neoantigens found in a patient's tumour. This personalised method improves vaccine efficacy by maximising the immune response to tumor-specific antigens.

Combination Treatments: There is an increasing interest on combining cancer vaccines with other immunotherapies such as checkpoint inhibitors and cytokine treatments to improve treatment outcomes. The synergistic effects of vaccines and immunomodulatory drugs aim to increase immunological activation, overcome immune suppression in the tumour microenvironment, and improve patient response to therapy.

Innovations in Vaccination Delivery Technologies: They are increasing vaccine potency and efficacy. Nanoparticles, viral vectors, and dendritic cell-based vaccinations allow for targeted antigen delivery, extended antigen presentation, and increased immune activation. These improvements aim to improve vaccination efficacy while minimising side effects, hence speeding the development of next-generation cancer vaccines.

Cancer Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the cancer vaccine market:

North America:

According to Verified Market Research analyst, the biggest market share for cancer vaccine market is held by the North America region. The region benefits from strong research and development capabilities which are supported by considerable financing and infrastructure. Leading pharmaceutical corporations and research institutions in North America are driving innovation in cancer vaccine technology accelerating clinical trials and bringing new medicines to market.

North America's regulatory systems are beneficial to expediting vaccine research and licensure. Agencies such as the FDA in the United States streamline regulatory routes for biologics including vaccines allowing for faster market access than other regions. This regulatory efficiency promotes investment and fosters a competitive environment in which businesses can quickly introduce novel cancer vaccines to patients.

North America's robust healthcare environment and high healthcare spending encourage widespread acceptance of novel therapeutics such as cancer vaccinations. The region's well-established healthcare infrastructure provides patients with access to cutting-edge therapies creating a favourable climate for the commercialization and adoption of new vaccinations. Collaborations among academia, industry, and healthcare providers also enhance knowledge exchange and the application of innovative immunotherapies, thereby consolidating North America's leadership in the worldwide cancer vaccine market.

Asia-Pacific:

Asia-Pacific is seeing a rapid growth in cancer vaccine market. The region's fast-growing population and rising cancer incidence fuel need for novel therapeutic alternatives including cancer vaccinations. Cancer incidences are increasing in countries such as China, India, and Japan as a result of ageing populations, lifestyle changes, and environmental factors driving the market for cancer vaccines.

The Asia-Pacific region benefits from increased investments in healthcare infrastructure and research capacity. Governments and commercial sectors across the area are investing heavily in healthcare systems and biopharmaceutical research and development. This investment promotes improvements in cancer vaccine technology, clinical trials, and regulatory approvals which contribute to the market's rapid expansion.

Adoption of cancer vaccines in Asia-Pacific is being driven by altering healthcare regulations and increased understanding among healthcare professionals and patients about the benefits of immunotherapy and personalised medicine. The region's various demographic and genetic profiles need specialised treatment approaches which are consistent with the personalised medicine trend of emphasising targeted therapies based on specific patient traits.

Cancer Vaccine Market: Segmentation Analysis

The cancer vaccine market is segmented on the basis of Type of Vaccine, Type of Cancer, Technology, End User and Geography.

Cancer Vaccine Market, By Type of Vaccine

  • Preventive
  • Therapeutic

Based on Type of Vaccine, the market is bifurcated into Preventive and Therapeutic. Therapeutic cancer vaccines presently dominate the market since they are designed to treat existing cancer cases. These vaccinations activate the immune system to recognise and target cancer cells which could halt disease development and improve patient outcomes. While preventive vaccines such as those for HPV are critical in lowering cancer incidence, therapeutic vaccines target current medical requirements and show great potential in improving cancer treatment options through personalised immunotherapy techniques.

Cancer Vaccine Market, By Type of Cancer

  • Cervical Cancer
  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer

Based on Type of Cancer, the market is bifurcated into Cervical Cancer, Prostate Cancer, Lung Cancer, Breast Cancer. Breast cancer dominates because of its large global prevalence and substantial research into therapeutic approaches such as vaccinations, that target specific breast cancer antigens to improve treatment outcomes and survival rates.

Cancer Vaccine Market, By Technology

  • Peptide-based vaccines
  • Dendritic cell vaccines
  • Vector-based vaccines
  • DNA/RNA-based vaccines

Based on Technology, the market is bifurcated into Peptide-based vaccines, Dendritic cell vaccines, Vector-based vaccines, DNA/RNA-based vaccines. Peptide-based vaccines now dominate the cancer vaccine landscape due to their precision in targeting tumour antigens which improves immune responses against cancer cells while minimising off-target effects making them ideal candidates for personalised immunotherapy techniques.

Cancer Vaccine Market, By End-User

  • Hospitals and clinics
  • Cancer Research Institutes
  • Biopharmaceutical Companies
  • Governmental and nonprofit organizations

Based on End-User, the market is bifurcated into Hospitals and clinics, Cancer Research Institutes, Biopharmaceutical Companies, Governmental and nonprofit organizations. Hospitals and clinics dominate because they provide direct immunisation, cancer treatment, and diagnosis services to patients offering comprehensive healthcare delivery and cancer-related needs management.

Cancer Vaccine Market, By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Middle East
  • Latin America

Based on regional analysis, The market is divided into four regions: North America, Europe, Asia Pacific, and Latin America, the Middle East, and Africa. Several major reasons contribute to North America's present dominance in the global cancer vaccine industry. The region benefits from modern healthcare infrastructure, major expenditures in R&D, and a strong regulatory environment that facilitates the prompt approval and marketing of novel treatments. Leading pharmaceutical corporations in North America are pioneering the development of novel cancer vaccines employing large clinical trial networks and collaborations with premier research institutes. Furthermore, high healthcare spending and a huge patient population help to drive wider adoption of cancer vaccinations cementing North America's leadership in this crucial healthcare sector.

Key Players

  • The Global Cancer vaccine market study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline, Merck & Co., Pfizer Inc., Sanofi Pasteur, CSL Limited, Astellas Pharma Inc., and Serum Institute of India.

Our market analysis also includes a part dedicated specifically to such significant firms, in which our experts provide insights into their financial statements, as well as product benchmarking and SWOT analysis. The competitive landscape section also contains important development strategies, market share, and market ranking analysis for the aforementioned competitors worldwide.

  • Cancer Vaccine Market Recent Developments:
  • In September 2023, The Federal Government of Nigeria's impending initiative to save hundreds of lives in the nation, the launch of (HPV) Human papillomavirus (HPV) vaccine, would reduce the number of cervical cancer cases in teenage girls in the country.
  • In January 2022, following the release of mRNA vaccines against coronavirus, Moderna and Biotech, both biotech companies, announced that they are working on cancer vaccines. Sam Godfrey, senior research information manager at Cancer Research U.K. (CRUK), spoke on the push for development into mRNA cancer vaccines.
  • In August 2023, The Minister for Health, Stephen Donnelly TD, announced that Laura Brennan's HPV (Human Papillomavirus) Vaccine Catch-Up Programme would be expanded. The programme will encompass all guys aged up to 22 years.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Cancer Vaccine Market, By Type of Vaccine

  • Preventive vaccinations
  • Therapeutic vaccines

5. Cancer Vaccine Market, By Type of Cancer

  • Cervical Cancer
  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Other Forms of Cancer

6. Cancer Vaccine Market, By Technology

  • Peptide-based vaccines
  • Dendritic cell vaccines
  • Vector-Based Vaccines
  • DNA/RNA-Based Vaccines

7. Cancer Vaccine Market, By End User

  • Hospitals and clinics
  • Cancer Research Institutes
  • Biopharmaceutical Companies
  • Governmental and nonprofit organizations

8. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

9. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

10. Competitive Landscape

  • Key Players
  • Market Share Analysis

11. Company Profiles

  • ABB (Switzerland)
  • Siemens AG (Germany)
  • Wartsila (Finland)
  • Kongsberg Gruppen (Norway)
  • Leclanche S.A. (Switzerland)
  • General Dynamics Electric Boat (USA)
  • Corvus Energy (Norway)

12. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

13. Appendix

  • List of Abbreviations
  • Sources and References